ERBB2 and triple-negative breast carcinoma: Pertuzumab significantly attenuated in vivo tumorigenicity in triple-negative breast cancer (TNBC) cells expressing circ-HER2/HER2–103, but did not affect tumorigenicity in circ-HER2/HER2–103 negative TNBC cells.